reports
InvestmentPitch Media Video Discusses Resverlogix and its Focus on Apa...
InvestmentPitch Media Video Discusses Resverlogix and its Focus on Apabetalone’s Future Development for the Prevention and Treatment of Post COVID-19 Conditions VANCOUVER, British Columbia, Sept. 30, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. (TSX:RVX) (OTCPink:RVXCF), a world leader in epigenetics, or gene regulation, announced that apabetalone’s future development related to COVID-19, will focus on the prevention and treatment of Post COVID-19 Conditions. The company’s new focus on patients with Post COVID-19 Conditions (PCC), colloquially known as long-COVID, as opposed to hospitalized...
Resverlogix Confirms Focus on Treatment of Post COVID-19 Conditions
Resverlogix Confirms Focus on Treatment of Post COVID-19 Conditions CALGARY, Alberta, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the “Company”) (TSX:RVX) today announced that apabetalone’s future clinical development related to COVID-19 will focus on the prevention and treatment of Post COVID-19 Conditions (PCC), colloquially known as long-COVID, as opposed to hospitalized COVID-19 patients, reflecting the compelling opportunity for apabetalone to benefit PCC patients and guidance from the US Food and Drug Administration (FDA). A recent from the US Centers fo...
Resverlogix Publishes New Data Highlighting Apabetalone’s Benefit in N...
Resverlogix Publishes New Data Highlighting Apabetalone’s Benefit in Non-alcoholic Fatty Liver Disease CALGARY, Alberta, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) today announced the publication of an article entitled “Reduction in the Risk of Major Adverse Cardiovascular Events with the BET Protein Inhibitor Apabetalone in Patients with Recent Acute Coronary Syndrome, Type 2 Diabetes, and Moderate to High Likelihood of Non-Alcoholic Fatty Liver Disease” in the American Journal of Preventive Cardiology. The article presents a post-hoc analysis of BETonM...
Resverlogix Announces Appointment of New Chief Scientific Officer
Resverlogix Announces Appointment of New Chief Scientific Officer CALGARY, Alberta, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) today announced the appointment of Dr. Ewelina Kulikowski, Ph.D. as Chief Scientific Officer. Dr. Norman Wong is retiring as CSO, effective today. “Dr. Kulikowski has a contributed tremendously since joining Resverlogix in 2005 and we are delighted to appoint her CSO,” said Donald McCaffrey, President and CEO of Resverlogix, adding “We would like to sincerely thank Dr. Wong for his innumerable contributions since co-founding Res...
Resverlogix Announces Voting Results from the 2022 Meeting of Sharehol...
Resverlogix Announces Voting Results from the 2022 Meeting of Shareholders CALGARY, Alberta, June 21, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix”, or the "Corporation") (TSX:RVX) today held its Annual Meeting of Shareholders (the “Meeting”) in Calgary, Alberta. During business proceedings at the Meeting, shareholders elected five (5) Board members until the next annual meeting. The voting results of shares represented at the Meeting for individual directors were as follows: Votes ForVotes WithheldPercent ForPercent WithheldDonald J. McCaffre...
Resverlogix Announces New Research Findings Highlighting the Safety of...
Resverlogix Announces New Research Findings Highlighting the Safety of BD2-selective BET Inhibitors CALGARY, Alberta, June 08, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) today announced the publication of an article entitled “Breaking boundaries: Pan BETi disrupt 3D chromatin structure, BD2-selective BETi are strictly epigenetic transcriptional regulators” in the journal Biomedicine & Pharmacotherapy. The article uncovers a clear mechanism for the improved safety, and reduced off-target effects, seen with BD2-selective BET inhibitors in comparison with non-select...
Resverlogix Announces Type C Meeting with FDA for CORAL, a Phase 3 Hig...
Resverlogix Announces Type C Meeting with FDA for CORAL, a Phase 3 High-risk COVID-19 Outpatient Study CALGARY, Alberta, May 09, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix", or "the Company") (TSX:RVX), in partnership with EVERSANA™, today announced that the U.S. Food and Drug Administration (FDA) has granted the Company’s request for a Type C meeting to review the clinical trial protocol for its Phase 3 study of apabetalone in high-risk COVID-19 outpatients. The meeting is scheduled for early August. In response to the transformation of the COVID-19 pandemic, advancement t...
Resverlogix Announces One-Year Extension of Debenture
Resverlogix Announces One-Year Extension of Debenture CALGARY, Alberta, April 19, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the “Company”) (TSX:RVX) announced today that it has closed a one-year extension of Company’s US$6.0 million 10% secured convertible debenture with Shenzhen Hepalink Pharmaceutical Group Co., Ltd. ("Hepalink"), and payment of accrued interest thereon, extending the maturity date to May 13, 2023. “We are extremely pleased that our partner Hepalink has extended the debenture’s maturity date. This speaks volumes to the ongoing supportive and co...
Apabetalone’s Positive Impact on Pulmonary Arterial Hypertension Publi...
Apabetalone’s Positive Impact on Pulmonary Arterial Hypertension Published in the American Journal of Respiratory and Critical Care Medicine CALGARY, Alberta, March 17, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) today announced the publication of an article entitled “BET Protein Inhibition for Pulmonary Arterial Hypertension: A Pilot Clinical Study” in the prestigious American Journal of Respiratory and Critical Care Medicine – which has an of 21.4. The article outlines the positive impact of apabetalone in the investigator-led pulmonary arterial hypertension (P...
Resverlogix Expands Phase 2b Clinical Trial for COVID-19 Treatment wit...
Resverlogix Expands Phase 2b Clinical Trial for COVID-19 Treatment with First Site in Brazil and Second in Canada CALGARY, Alberta, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) today announced that the first Brazilian site has been initiated for its Phase 2b study to evaluate the safety and efficacy of Canadian-developed apabetalone as a potential oral treatment for COVID-19. Additionally, the second Canadian site, in Calgary, Alberta, has also been initiated. A further five sites in Brazil and a third Canadian site, in Toronto, Ontario, will also be comin...
Resverlogix annonce le début du recrutement et du dosage des patients ...
Resverlogix annonce le début du recrutement et du dosage des patients pour un essai de phase 2b d’un traitement prometteur contre la COVID-19 développé au Canada CALGARY, Alberta, 18 janv. 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. (« Resverlogix ») (TSX:RVX) a annoncé aujourd’hui que le recrutement et le dosage des patients ont commencé dans le cadre d’une étude de phase 2b, dans un centre de l’Hôpital de l’Université de l’Alberta à Edmonton. L’essai évaluera l’innocuité et l’efficacité de l’apabétalone en tant que traitement oral potentiel pour la COVID-19. Le double mécanisme épigénét...
Resverlogix Announces Commencement of Patient Enrollment and Dosing in...
Resverlogix Announces Commencement of Patient Enrollment and Dosing in a Phase 2b Trial for a Promising Canadian-Developed COVID-19 Treatment CALGARY, Alberta, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) is pleased to announce today that enrollment and dosing of patients has commenced in a Phase 2b study at a site at the University of Alberta Hospital in Edmonton. The trial will evaluate the safety and efficacy of apabetalone as a potential oral treatment for COVID-19. Apabetalone’s unique dual epigenetic mechanism may help stop disease progression by ...
Resverlogix Announces Corporate Update Webcast and Conference Call
Resverlogix Announces Corporate Update Webcast and Conference Call CALGARY, Alberta, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) today announced that they will be hosting a corporate update webcast and conference call on Thursday, December 16th, 2021 at 2:00 pm MST. Webcast link: Conference call information: Canada/USA TF: 1-800-319-4610Toronto Toll: About Apabetalone Apabetalone (RVX-208), is a first-in-class, small molecule, therapeutic candidate with an epigenetic mechanism of action. It is a BD2 (bromodomain) selective BET (bromodoma...
Resverlogix Enters into a Cooperation Agreement with the Supreme Counc...
Resverlogix Enters into a Cooperation Agreement with the Supreme Council of the Arab-African Economy to Support the Development of Apabetalone for COVID-19 Patients This initiative will provide the necessary investments to advance first-in-class drug - apabetalone for the potential treatment of COVID-19 within the Arab-African Economy CALGARY, Alberta, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix” or the Company”) (TSX: RVX), a world leader in epigenetics or gene regulation, is pleased to announce today that it has entered into a cooperation agreement with the Supre...
Resverlogix In Active Discussions With The Kingdom of Morocco’s Minist...
Resverlogix In Active Discussions With The Kingdom of Morocco’s Ministry of Health For The Launch Of COVID-19 Clinical Studies With First-In-Class Drug Apabetalone CALGARY, Alberta, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX: RVX), a world leader in epigenetics or gene regulation, is pleased to announce today that it is in active discussions with the Kingdom of Morocco’s Ministry of Health for possible Phase 2 COVID-19 clinical studies within their hospitals using first-in-class drug – apabetalone. “We are pleased to collaborate with the Kin...
Resverlogix to Participate in Leading Scientific Conferences
Resverlogix to Participate in Leading Scientific Conferences Presentations will Showcase Research by Resverlogix Scientists, Advancing our Understanding of Epigenetics in Chronic Diseases CALGARY, Alberta, Oct. 29, 2021 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix” or the Company”) (TSX: RVX), a world leader in epigenetics or gene regulation, today announces its virtual participation at the following scientific conferences: American Society of Nephrology – (November 2-7) Research Scientist Dean Gilham, PhD will present a poster entitled: “Apabetalone Downregulates Fibrotic, Inf...
Resverlogix to Present at Upcoming Conferences
Resverlogix to Present at Upcoming Conferences Presentation Highlights will Include First-in-Class Epigenetic Small Molecule Candidate Apabetalone Being Evaluated as Potential Treatment for COVID-19 CALGARY, Alberta, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix” or the Company”) (TSX: RVX), a world leader in epigenetics or gene regulation, announces today that President and CEO Donald McCaffrey will be presenting virtually at the following conferences: 14th Annual LD Micro Main Event Conference Resverlogix will give a virtual presentation at the LD Micro Main Eve...
Resverlogix Receives Ethics Approval for Canadian Sites in Apabetalone...
Resverlogix Receives Ethics Approval for Canadian Sites in Apabetalone COVID-19 Clinical Trial Study Approval Paves the Way for Trial Participants to Begin Taking Apabetalone CALGARY, Alberta, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX), today announces the approval of its COVID-19 clinical trial of apabetalone by the Health Research Ethics Board (HREB) – Biomedical Panel at the University of Alberta. This approval allows for recruitment in the trial to commence. “The ethics board approval is an important step towards bringing apabetal...
Study Demonstrates Resverlogix’s Apabetalone Treatment Significantly I...
Study Demonstrates Resverlogix’s Apabetalone Treatment Significantly Improves Cognition and Reduces Cognitive Decline Among Patients with Both Cardiovascular Disease and Diabetes Mellitus Positive Findings in Journal of Alzheimer's Disease Suggest BET Inhibitor Apabetalone Holds Promise as a Safe and Effective Therapeutic for Vascular Cognitive Impairment Apabetalone is a First-in-Class Oral Epigenetic Therapeutic Candidate which Positively Regulates and Normalizes Genes that Cause Chronic Illness CALGARY, Alberta, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or t...
Resverlogix Announces Apabetalone Meets Primary Endpoint in a Pulmonar...
Resverlogix Announces Apabetalone Meets Primary Endpoint in a Pulmonary Arterial Hypertension Pilot Study Apabetalone, a First-in-Class Epigenetic Therapeutic Candidate, Met Key Endpoint of Lowering Pulmonary Vascular Resistance (PVR) and Was Well Tolerated Successful Completion and Promising Results of Investigator-led APPROACH-p Trial Sets the Stage for a Larger Multicenter Trial CALGARY, Alberta, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX), a world leader in epigenetics, or gene regulation, today announces that its investigational e...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.